Human Serum Albumin

Human Serum Albumin Global Market Outlook

• Human blood plasma is the source of HSA, the supply of plasma would impact the supply of HSA

• Albumin is used to treat several conditions, such as cardiac surgery, liver disease, severe infections, burns, treatment of shock, etc.

• The US has the maximum number of plasma collection centers, followed by Europe and the Asia Pacific regions

• China is the largest market for HSA, China accounts for ~50 percent of the market share globally

• The albumin market is forecasted to reach approximately 2001 tons by 2027

Human Serum Albumin Market Overview

• The global albumin market is expected to reach ~7.6 billion by 2028 with a CAGR ranging between 5 and 6 percent

• The HSA is manufactured from two different sources, the widely preferred source is human blood plasma. The plasma-derived HSA is used in treating clinical conditions

• The other type of HSA is recombinant, which is produced from recombinant cells and harvested. This particular type is growing in the market since they do not have the risk of contaminants unlike plasma-derived HSA

• Recombinant HSA is widely used for research purposes and as a supplement to cell culture media

• Around 209 tons of China’s albumin is produced by domestic suppliers and around 411 tons of China’s albumin is produced by Multinational Corporations

Drivers and Constraints : Human Serum Albumin

• The demand for HSA is the maximum constituent in the human blood plasma, the supply of blood plasma affects the supply of HAS.

Drivers

• The demand for HSA in plasma replacement therapy, cardiac surgery, liver disease, severe infections, burns, treatment of shock, etc., are the major market drivers

• HSA has various other commercial applications, including drug delivery, vaccine ingredients, cell culture media supplements, sealant in surgeries, and coatings for medical equipment

• Investments for research and development of production technologies of HSA are the major driving factors in the market

Constraints

• The plasma supply is dependent on the donation rates in the particular region

• Stringent regulatory norms in the collection of whole blood, plasma, testing, and fractionation of plasma are major factors that slow down the market growth

• The production of plasma-derived proteins is capital-intensive and time-consuming